Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ombrabulin - Sanofi

Drug Profile

Ombrabulin - Sanofi

Alternative Names: AC 7700; AVE-8062; AVE8062A; RPR258063

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ajinomoto
  • Developer Sanofi
  • Class Amides; Antineoplastics; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Apr 2018 Sanofi terminates a phase I trial due to the occurrence of DLTs in cycle 1 in Solid tumours (Combination therapy) in Japan (IV)
  • 01 Nov 2014 Sanofi completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in France, Italy, United Kingdom (NCT01193595)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top